drugset / Trial / NCT07246707
KSV01 Injection as the Therapy for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
NaSingle-groupOpen-labelTreatment
Summary
This is a single center, single arm, open-label, dose escalation, phase 1 study to evaluate the safety, tolerability and preliminary efficacy of KSV01 injection for patients with relapsed/refractory B-Cell acute lymphoblastic leukemia (r/r B-ALL).
Timeline
- Start
- 2026-01-02
- Primary completion
- 2027-10
- Completion
- 2028-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | KSV01 | Unknown | — | — |
Indications
No indication recorded.